Juan E. Grunwald
YOU?
Author Swipe
View article: Onset of End-Stage Atrophic Age-Related Macular Degeneration as an End Point—A Delphi Study: Classification of Atrophy Meetings Report 7
Onset of End-Stage Atrophic Age-Related Macular Degeneration as an End Point—A Delphi Study: Classification of Atrophy Meetings Report 7 Open
View article: Prediction for 2-Year Vision Outcomes Using Early Morphologic and Functional Responses in the Comparison of Age-related Macular Degeneration Treatments Trials
Prediction for 2-Year Vision Outcomes Using Early Morphologic and Functional Responses in the Comparison of Age-related Macular Degeneration Treatments Trials Open
View article: Thiazolidinedione use and retinal fluid in the comparison of age-related macular degeneration treatments trials
Thiazolidinedione use and retinal fluid in the comparison of age-related macular degeneration treatments trials Open
Background Thiazolidinediones, commonly used antidiabetic medications, have been associated with an increased risk of development of diabetic macular oedema and increased vascular endothelial cell permeability. Macular neovascularisation i…
View article: Predominantly Persistent Intraretinal Fluid in the Comparison of Age-related Macular Degeneration Treatments Trials
Predominantly Persistent Intraretinal Fluid in the Comparison of Age-related Macular Degeneration Treatments Trials Open
View article: Predominantly Persistent Subretinal Fluid in the Comparison of Age-Related Macular Degeneration Treatments Trials
Predominantly Persistent Subretinal Fluid in the Comparison of Age-Related Macular Degeneration Treatments Trials Open
View article: SYSTEMIC MEDICATION USE AND THE INCIDENCE AND GROWTH OF GEOGRAPHIC ATROPHY IN THE COMPARISON OF AGE-RELATED MACULAR DEGENERATION TREATMENTS TRIALS
SYSTEMIC MEDICATION USE AND THE INCIDENCE AND GROWTH OF GEOGRAPHIC ATROPHY IN THE COMPARISON OF AGE-RELATED MACULAR DEGENERATION TREATMENTS TRIALS Open
Purpose: To determine associations of systemic medications with the incidence and growth of geographic atrophy (GA) in participants of the comparison of age-related macular degeneration treatments trials. Methods: Participants of compariso…
View article: Localized Optical Coherence Tomography Precursors of Macular Atrophy and Fibrotic Scar in the Comparison of Age-Related Macular Degeneration Treatments Trials
Localized Optical Coherence Tomography Precursors of Macular Atrophy and Fibrotic Scar in the Comparison of Age-Related Macular Degeneration Treatments Trials Open
View article: Progression of retinopathy and incidence of cardiovascular disease: findings from the Chronic Renal Insufficiency Cohort Study
Progression of retinopathy and incidence of cardiovascular disease: findings from the Chronic Renal Insufficiency Cohort Study Open
Purpose Chronic kidney disease (CKD) patients often develop cardiovascular disease (CVD) and retinopathy. The purpose of this study was to assess the association between progression of retinopathy and concurrent incidence of CVD events in …
View article: BETA-PERIPAPILLARY ATROPHY AND GEOGRAPHIC ATROPHY IN THE COMPARISON OF AGE-RELATED MACULAR DEGENERATION TREATMENTS TRIALS
BETA-PERIPAPILLARY ATROPHY AND GEOGRAPHIC ATROPHY IN THE COMPARISON OF AGE-RELATED MACULAR DEGENERATION TREATMENTS TRIALS Open
Purpose: To determine associations between beta-peripapillary atrophy (B-PPA) and incidence and growth of geographic atrophy (GA) in eyes treated with anti–vascular endothelial growth factor agents in the Comparison of Age-Related Macular …
View article: Orally Administered Alpha Lipoic Acid as a Treatment for Geographic Atrophy
Orally Administered Alpha Lipoic Acid as a Treatment for Geographic Atrophy Open
View article: Incidence and Progression of Nongeographic Atrophy in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Clinical Trial
Incidence and Progression of Nongeographic Atrophy in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Clinical Trial Open
ClinicalTrials.gov Identifier: NCT00593450.
View article: Characteristics of Eyes With Good Visual Acuity at 5 Years After Initiation of Treatment for Age-Related Macular Degeneration but Not Receiving Treatment From Years 3 to 5
Characteristics of Eyes With Good Visual Acuity at 5 Years After Initiation of Treatment for Age-Related Macular Degeneration but Not Receiving Treatment From Years 3 to 5 Open
ClinicalTrials.gov Identifier: NCT00593450.
View article: Incomplete Retinal Pigment Epithelial and Outer Retinal Atrophy in Age-Related Macular Degeneration
Incomplete Retinal Pigment Epithelial and Outer Retinal Atrophy in Age-Related Macular Degeneration Open
View article: Association Between Cilioretinal Arteries and Advanced Age-Related Macular Degeneration
Association Between Cilioretinal Arteries and Advanced Age-Related Macular Degeneration Open
ClinicalTrials.gov identifier: NCT00593450.
View article: Incidence and Features of Geographic Atrophy in Fellow Eyes in the Comparison of Age-related Macular Degeneration Treatment Trials (CATT)
Incidence and Features of Geographic Atrophy in Fellow Eyes in the Comparison of Age-related Macular Degeneration Treatment Trials (CATT) Open
View article: Association Between Progression of Retinopathy and Concurrent Progression of Kidney Disease
Association Between Progression of Retinopathy and Concurrent Progression of Kidney Disease Open
Progression of retinopathy appears to be associated with progression of CKD on univariable analysis but not on multivariable analysis suggesting that similar risk factors may be affecting the progression of both retinal and chronic kidney …
View article: Distribution of OCT Features within Areas of Macular Atrophy or Scar after 2 Years of Anti-VEGF Treatment for Neovascular AMD in CATT
Distribution of OCT Features within Areas of Macular Atrophy or Scar after 2 Years of Anti-VEGF Treatment for Neovascular AMD in CATT Open
View article: Five-Year Follow-up of Nonfibrotic Scars in the Comparison of Age-Related Macular Degeneration Treatments Trials
Five-Year Follow-up of Nonfibrotic Scars in the Comparison of Age-Related Macular Degeneration Treatments Trials Open
View article: Macular Morphology and Visual Acuity in Year Five of the Comparison of Age-related Macular Degeneration Treatments Trials
Macular Morphology and Visual Acuity in Year Five of the Comparison of Age-related Macular Degeneration Treatments Trials Open
View article: ASSOCIATION BETWEEN ORAL IRON SUPPLEMENTATION AND RETINAL OR SUBRETINAL HEMORRHAGE IN THE COMPARISON OF AGE-RELATED MACULAR DEGENERATION TREATMENT TRIALS
ASSOCIATION BETWEEN ORAL IRON SUPPLEMENTATION AND RETINAL OR SUBRETINAL HEMORRHAGE IN THE COMPARISON OF AGE-RELATED MACULAR DEGENERATION TREATMENT TRIALS Open
Purpose: Because patients often take iron supplements without medical indication, and iron can accumulate in vascular endothelial cells, the authors evaluated the association of oral iron supplementation with retinal/subretinal hemorrhage …
View article: Association between Oral Iron Supplementation and Retinal or Subretinal Hemorrhage in the Comparison of Age-Related Macular Degeneration Treatments Trials
Association between Oral Iron Supplementation and Retinal or Subretinal Hemorrhage in the Comparison of Age-Related Macular Degeneration Treatments Trials Open
View article: Association of Pulse Wave Velocity With Chronic Kidney Disease Progression and Mortality
Association of Pulse Wave Velocity With Chronic Kidney Disease Progression and Mortality Open
Patients with chronic kidney diseases (CKDs) are at risk for further loss of kidney function and death, which occur despite reasonable blood pressure treatment. To determine whether arterial stiffness influences CKD progression and death, …
View article: Development and Course of Scars in the Comparison of Age-Related Macular Degeneration Treatments Trials
Development and Course of Scars in the Comparison of Age-Related Macular Degeneration Treatments Trials Open
View article: Baseline Predictors for Five-Year Visual Acuity Outcomes in the Comparison of AMD Treatment Trials
Baseline Predictors for Five-Year Visual Acuity Outcomes in the Comparison of AMD Treatment Trials Open
View article: Consensus Definition for Atrophy Associated with Age-Related Macular Degeneration on OCT
Consensus Definition for Atrophy Associated with Age-Related Macular Degeneration on OCT Open
View article: Linking optical coherence tomographic, angiographic and photographic lesion components in neovascular age-related macular degeneration in the Comparison of Age-related Macular Degeneration Treatments Trials
Linking optical coherence tomographic, angiographic and photographic lesion components in neovascular age-related macular degeneration in the Comparison of Age-related Macular Degeneration Treatments Trials Open
View article: Baseline Predictors of Five-Year Visual Acuity in the Comparison of AMD Treatment Trials (CATT)
Baseline Predictors of Five-Year Visual Acuity in the Comparison of AMD Treatment Trials (CATT) Open
View article: Incidence and risk factors for neovascular AMD in the fellow eye in the Comparison of AMD Treatment Trials (CATT) Follow-up Study
Incidence and risk factors for neovascular AMD in the fellow eye in the Comparison of AMD Treatment Trials (CATT) Follow-up Study Open
View article: Distribution of optical coherence tomographic morphologic components within areas appearing as atrophic or scarred after two years of anti-VEGF treatment for neovascular age-related macular degeneration in the Comparison of Age-related Macular Degeneration Treatments Trials
Distribution of optical coherence tomographic morphologic components within areas appearing as atrophic or scarred after two years of anti-VEGF treatment for neovascular age-related macular degeneration in the Comparison of Age-related Macular Degeneration Treatments Trials Open
View article: Association between pseudodrusen and delayed patchy choroidal filling in the comparison of age‐related macular degeneration treatments trials
Association between pseudodrusen and delayed patchy choroidal filling in the comparison of age‐related macular degeneration treatments trials Open
Pseudodrusen have been identified as a strong risk factor for development of late age-related macular degeneration (AMD; Alten & Eter 2015; Chang et al. 2016; Zhou et al. 2016) and macular atrophy (Munk et al. 2016). However, the pathophys…